BOSTON--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ ...

-- Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 ...

Drugs made of mRNA have the potential to transform medicine—if only they could get into cells in one piece. Now, University ...

Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced that Jake Becraft, PhD, Co-founder and Chief Executive Officer, will present at the 44th Annual J.P. Morgan ...

Researchers shamelessly copy viral strategies to get mRNA medicines into cells in one piece (Illustration courtesy of Joe Luciani ...

Leader in mRNA therapeutics strengthens clinical development expertise with globally recognized oncology innovator Strand Therapeutics, the leader in programmable mRNA medicines, today announced the ...

The same groundbreaking technology that enabled rapid COVID-19 vaccine development is now poised to revolutionize medicine in ways that seemed impossible just a few years ago. Messenger RNA vaccines ...